Effects on Glutamine on the Outcome of Allogeneic Bone Marrow Transplant Recipients
NCT ID: NCT00563498
Last Updated: 2010-07-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
40 participants
INTERVENTIONAL
2004-07-31
2006-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Outcomes of MF Patients Exposure to Ruxolitinib During Transplantation
NCT04526223
Glutamine in Treating Side Effects in Children Who Are Undergoing Stem Cell Transplantation
NCT00003898
Pharmacologic Pretransplant Immunosuppression (PTIS) + Reduced Toxicity Conditioning (RTC) Allogeneic Stem Cell Transplantation in Inherited Hematologic Disorders
NCT05293509
Allogeneic Bone Marrow Transplantation in Patients With Primary Immunodeficiencies
NCT00006054
Prophylactic Intervention for Relapse Prevention Post-Allogeneic Transplantation in Very High-Risk MDS Patients Based on IPSS-M Stratification
NCT06612944
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Glutamine
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
The University of Hong Kong
OTHER
Fresienius Kabi HK Ltd
UNKNOWN
Hospital Authority, Hong Kong
OTHER_GOV
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Albert Lie, Dr
Role: PRINCIPAL_INVESTIGATOR
Department of Medicine/Division of Haematology, Queen Mary Hospital/ The University of Hong Kong
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Queen Mary Hospital
Hong Kong, , China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HARECCTR0500034
Identifier Type: -
Identifier Source: secondary_id
EC1432-00
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.